Neutralizing antibodies (nAbs) are important assets to fight COVID-19, but most existing
nAbs lose the activities against Omicron subvariants. Here, we report a human monoclonal …

The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis,
presenting a broad range of challenges. To help address some of the main problems, the …

Mutations and transient conformational movements of the receptor binding domain (RBD)
that make neutralizing epitopes momentarily unavailable present immune escape routes for …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …

The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
the cause of the coronavirus disease (COVID-19) pandemic. As of August 2021, more than …

Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a
potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute …

ABSTRACT Introduction Neutralizing antibodies (NAbs) that target key domains of the spike
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

The emergence of new variants of SARS-CoV-2 necessitates unremitting efforts to discover
novel therapeutic monoclonal antibodies (mAbs). Here, we report an extremely potent mAb …